Modeling microbial drug-resistance: from mathematics to pharmacoeconomics
Complicated intra-abdominal infection (IAI) requires increased health care expenditures and additional resources to compensate for an ineffective starting therapy.Aim. To select the economically optimal algorithm for using antimicrobial agents (AMA) that would minimize the evolving drug-resistance o...
Saved in:
Main Authors: | Yu. M. Gomon (Author), M. A. Arepyeva (Author), Yu. E. Balykina (Author), A. S. Kolbin (Author), A. A. Kurylev (Author), M. A. Proskurin (Author), S. V. Sidorenko (Author) |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2018-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic analysis of denosumab in patients with breast cancer and bone metastases
by: A. S. Kolbin, et al.
Published: (2018) -
Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023) -
Pharmacoeconomic evaluation of ipragliflozin in combination with metformin in comparison with other regimens of therapy for type 2 diabetes mellitus
by: A. S. Kolbin, et al.
Published: (2021) -
Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation
by: A. S. Kolbin, et al.
Published: (2018) -
An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2019)